<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Drugs in pipeline for COVID-19
   <xref rid="bib4" ref-type="bibr">[4]</xref>, 
   <xref rid="bib5" ref-type="bibr">[5]</xref>, 
   <xref rid="bib6" ref-type="bibr">[6]</xref>
  </p>
 </caption>
 <alt-text id="alttext0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drugs</th>
    <th>Types</th>
    <th>Mechanisms of action</th>
    <th>Past evidences</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chloroquine</td>
    <td align="left">4-aminoquinoline</td>
    <td align="left">Not clearly known, changes the pH of endosomes and believed to prevent viral entry, transport and post-entry events</td>
    <td align="left">Inhibits infection of cells by SARS-CoV-2 
     <italic>in vitro</italic>, approved for malaria treatment and prophylaxis
    </td>
   </tr>
   <tr>
    <td align="left">Hydroxychloroquine</td>
    <td align="left">4-aminoquinoline</td>
    <td align="left">Not clearly known, changes the pH of endosomes and believed to prevents viral entry, transport and post-entry events</td>
    <td align="left">Inhibits infection of cells by SARS-CoV-2 
     <italic>in vitro,</italic> approved for malaria prophylaxis and autoimmune disease (e.g. rheumatic diseases). Approved for treatment of T2DM in India
    </td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">Adenosine nucleotide analogues</td>
    <td align="left">Inhibits viral application</td>
    <td align="left">Effective against SARS and MERS</td>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Nucleoside analogue</td>
    <td align="left">Inhibits viral RNA synthesis and mRNA capping</td>
    <td align="left">No evidence in SARS (potential harm) and MERS</td>
   </tr>
   <tr>
    <td align="left">Ribavirin plus Interferon</td>
    <td/>
    <td align="left">Inhibits viral replication</td>
    <td align="left">Mixed result against MERS</td>
   </tr>
   <tr>
    <td align="left">Camostat Mesilate</td>
    <td align="left">Protease inhibitors</td>
    <td align="left">Blocks viral maturation and entry to cells</td>
    <td align="left">Effectively blocked SARS-CoV-2 in lung cells 
     <italic>in vitro</italic>
    </td>
   </tr>
   <tr>
    <td align="left">Lopinavir/Ritonavir</td>
    <td align="left">Protease inhibitors</td>
    <td align="left">Blocks viral cellular entry</td>
    <td align="left">Effective against SARS-CoV-1 both 
     <italic>in vitro</italic> and human studies, approved for HIV-1 treatment
    </td>
   </tr>
   <tr>
    <td align="left">Darunavir/Cobicistat</td>
    <td align="left">Protease inhibitors</td>
    <td align="left">Blocks viral cellular entry</td>
    <td align="left">Established anti-HIV medication. No activity against coronaviruses or other respiratory viruses.
     <break/>No 
     <italic>in vitro</italic> or clinical data.
    </td>
   </tr>
   <tr>
    <td align="left">Favipiravir</td>
    <td align="left">RNA polymerase inhibitors</td>
    <td align="left">Inhibits viral RNA-dependent polymerase</td>
    <td align="left">Broad-spectrum anti-viral against influenza, arenavirus, bunyavirus and filovirus</td>
   </tr>
   <tr>
    <td align="left">Umifenovir</td>
    <td align="left">Fusion inhibitor</td>
    <td align="left">Inhibits fusion between viral and cellular membrane</td>
    <td align="left">Antiviral against other Corona viruses</td>
   </tr>
   <tr>
    <td align="left">Interferon-β1</td>
    <td align="left">Cytokines</td>
    <td align="left">Stimulate innate antiviral immunity.</td>
    <td align="left">MERS-CoV appears to be more sensitive than SARS-CoV 
     <italic>in vitro</italic> studies. Anti-MERS-CoV action noted in animal studies.
    </td>
   </tr>
   <tr>
    <td align="left">Interferon beta plus Lopinavir/Ritonavir</td>
    <td/>
    <td align="left">Interferon beta inhibits viral replication</td>
    <td align="left">Ongoing study for SARS-Cov-2 and MIRACLE trial for MERS</td>
   </tr>
   <tr>
    <td align="left">Aerosolized interferon α</td>
    <td align="left">Cytokines</td>
    <td align="left">Stimulate innate antiviral immunity.</td>
    <td align="left">Case report suggested benefit in MERS</td>
   </tr>
   <tr>
    <td align="left">Oseltamivir</td>
    <td align="left">Neuraminidase inhibitor</td>
    <td align="left">Inhibits viral replication</td>
    <td align="left">No effect in SARS 
     <italic>in vitro</italic> studies. No evidence in SARS and MERS
    </td>
   </tr>
   <tr>
    <td align="left">Baloxivir marboxil</td>
    <td align="left">Viral endonuclease inhibitor</td>
    <td align="left">Inhibits influenza virus multiplication</td>
    <td align="left">Approved for uncomplicated influenza only. Oral route.</td>
   </tr>
   <tr>
    <td align="left">Tocilizumab,
     <break/>Sarilumab
     <break/>Eculizumab
    </td>
    <td align="left">Monoclonal antibody</td>
    <td align="left">IL-6 inhibitor, blocks cytokine storm.</td>
    <td align="left">No data on SARS or MERS. Tocilizumab reduced fever and oxygen requirement in COVID-19, approved for rheumatoid arthritis.</td>
   </tr>
   <tr>
    <td align="left">SARS-Cov-2 specific protease drug candidate</td>
    <td align="left">Protease inhibitors</td>
    <td align="left">Blocks viral infectivity</td>
    <td align="left">No data available</td>
   </tr>
   <tr>
    <td align="left">SARS-Cov-2 specific antibodies</td>
    <td align="left">Antibody</td>
    <td align="left">Binds to virus and block infection, binds to infected cells and change the immune system</td>
    <td align="left">Inhibits SARS-CoV-2 entry into cells 
     <italic>in vitro</italic>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>SARS- severe acute respiratory syndrome, MERS- Middle-East respiratory syndrome, HIV- Human Immunodeficiency syndrome, T2DM – type 2 diabetes, COVID-19- Corona virus disease 19.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
